Account Manager-United Kingdom
D-Wave SystemsSalary not specified
- Full Time
- Junior (1 to 2 years)
About D-Wave Systems
D-Wave Systems focuses on quantum computing solutions for various industries, including manufacturing, logistics, biotech, and pharmaceuticals. Their products help businesses solve complex problems more efficiently, such as optimizing scheduling and resource allocation in manufacturing and logistics, as well as aiding drug discovery and medical imaging in biotech. D-Wave offers access to their quantum technology through hardware, software, and cloud services, generating revenue from these offerings and consulting services. They also support a community of developers with resources for creating new quantum applications. The Advantage2 prototype, featuring 1,200 qubits, significantly enhances performance for optimization tasks, making it useful for machine learning applications. D-Wave's goal is to enable businesses to leverage quantum technology for greater efficiency and innovation.
Burnaby, CanadaHeadquarters
1999Year Founded
$386.1MTotal Funding
IPOCompany Stage
Industrial & Manufacturing, AI & Machine Learning, BiotechnologyIndustries
201-500Employees
Benefits
Unlimited Paid Time Off
Parental Leave
Flexible Work Hours
Telehealth and Telemental Health
Learning and Development Opportunities
Risks
Potential quantum attack on classical encryption could undermine trust in their technology.
CEO's public disagreement with Nvidia's CEO may affect investor confidence.
Reliance on equity offerings for funding may indicate financial instability.
Differentiation
D-Wave is the first commercial supplier of quantum computers globally.
They uniquely offer both annealing and gate-model quantum computers.
Their Advantage2 prototype significantly advances quantum computing performance with 1,200 qubits.
Upsides
D-Wave secured $175 million to enhance quantum development and market strategies.
Strategic partnerships with NTT DOCOMO and Japan Tobacco Inc. boost industry credibility.
Quantum computing applications in logistics and biotech offer significant efficiency improvements.
Funding
Total raised$386.12 M
Latest valuation$1.20 B
StageIPO
POST IPO EQUITY
11/30/2024$175
POST IPO DEBT
3/31/2023$50
SPAC PRIVATE PLACEMENT
1/31/2022$40
$1.20 BSPAC IPO
1/31/2022$300
$1.20 BLATE VC
5/31/2020$38
$189.75 MCONVERTIBLE
1/31/2018$20
EARLY VC
9/30/2016$21
$105.00 MGROWTH EQUITY VC
6/30/2014$28
DEBT
2/29/2012$3